摘要
对于早期非小细胞肺癌,立体定向放射治疗(stereotactic body radiotherapy,SBRT)是不可手术患者的治疗首选。近些年的临床研究表明SBRT有较高的局控率和较低的毒副作用,整体疗效并不差于手术。不仅如此,SBRT的适应证也在逐渐扩大,甚至有学者提出了代替手术的可能性。全文对SBRT治疗早期非小细胞肺癌的应用进展作一综述。
Stereotactic body radiotherapy (SBRT) is the standard treatment for inoperable early stage non-small cell lung cancer (NSCLC). Recent researches have shown that SBRT has high local control rate and low toxicity comparable to those of surgery. Moreover, the indications of SBRT have gradually evolved,and it may even substitute surgery in the future. In this article,the progress of SBRT for inoperable early stage NSCLC is reviewed.
作者
郁肖夫
毛伟敏
郑晓
YU Xiao-fu;MAO Wei-min;ZHENG Xiao(Zhejiang Cancer Hospital,Hangzhou 310022,China)
出处
《肿瘤学杂志》
CAS
2018年第9期915-921,共7页
Journal of Chinese Oncology
基金
浙江省医药卫生科技项目(2016KYB043)
关键词
立体定向放射治疗
非小细胞肺癌
疗效
stereotactic body radiotherapy
non-small cell lung cancer
efficacy